Growing patient awareness about the benefits of personalized medicines is driving the adoption of molecular diagnostics, genomics, and proteomics technologies for infectious disease testing. Diagnostic tests can be used to assess the efficacy of specific therapeutic agents and treatments in patients. They help in determining the optimal dosages for drugs whose therapeutic effects vary widely depending on the patient.
Inadequate reimbursements impede the market growth; as per the MedPac (Medicare Payment Advisory Commission), medical testing witnessed a 40% decline in reimbursements. In 2012, Medicare revised its reimbursement mechanism for some IVD tests, including infectious diseases and molecular disease tests.
The leading players are heavily investing in R&D activities to develop advanced sequencing testing. For instance, Genapsys introduced ‘Genius’ an I-pad size sequencing platform with the ability to diagnose multiple molecules in a single run. Similarly, Stratos Genomics developed a fourth-generation sequencer based on sequencing by expansion (SBX), further driving the market growth.
Got questions about your regional growth of
Infectious Disease Testing Market?
Just drop us a line or call on +1 646 480 7505
Infectious Disease Testing Market Segmentation
By Product & Services
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now